Subject(s)
Chronic Disease/rehabilitation , Coronavirus Infections/rehabilitation , Critical Illness/rehabilitation , Pneumonia, Viral/rehabilitation , Survivorship , Anxiety/psychology , Anxiety/rehabilitation , Betacoronavirus , COVID-19 , Chronic Disease/psychology , Cognitive Dysfunction/rehabilitation , Contracture/rehabilitation , Critical Illness/psychology , Depression/psychology , Depression/rehabilitation , Humans , Intensive Care Units , Muscle Weakness/rehabilitation , Pandemics , Polyneuropathies/rehabilitation , Quality of Life , SARS-CoV-2 , Stress Disorders, Post-Traumatic/psychology , Stress Disorders, Post-Traumatic/rehabilitation , Wasting Syndrome/rehabilitationABSTRACT
AIMS: In acute heart failure (AHF), immobilization is caused because of unstable haemodynamics and dyspnoea, leading to protein wasting. Neuromuscular electrical stimulation (NMES) has been reported to preserve muscle mass and improve functional outcomes in chronic disease. NMES may be effective against protein wasting frequently manifested in patients with AHF; however, whether NMES can be implemented safely without any adverse effect on haemodynamics has remained unknown. This study aimed to examine the feasibility of NMES in patients with AHF. METHODS AND RESULTS: Patients with AHF were randomly assigned to the NMES or control group. The intensity of the NMES group was set at 10-20% maximal voluntary contraction level, whereas the control group was limited at a visible or palpable level of muscle contraction. The sessions were performed 5 days per week since the day after admission. Before the study implementation, we set the feasibility criteria with following items: (i) change in systolic blood pressure (BP) > ±20 mmHg during the first session; (ii) increase in heart rate (HR) > +20 b.p.m. during the first session; (iii) development of sustained ventricular arrhythmia, atrial fibrillation (AF), and paroxysmal supraventricular tachycardia during all sessions; (iv) incidence of new-onset AF during the hospitalization period < 40%; and (v) completion of the planned sessions by >70% of patients. The criteria of feasibility were set as follows; the percentage to fill one of (i)-(iii) was <20% of the total subjects, and both (iv) and (v) were satisfied. A total of 73 patients (median age 72 years, 51 men) who completed the first session were analysed (NMES group, n = 34; control group, n = 39). Systolic BP and HR variations were not significantly different between two groups (systolic BP, P = 0.958; HR, P = 0.665). Changes in BP > ±20 mmHg or HR > +20 b.p.m. were observed in three cases in the NMES group (8.8%) and five in the control group (12.8%). New-onset arrhythmia was not observed during all sessions in both groups. During hospitalization, one patient newly developed AF in the NMES group (2.9%), and one developed AF (2.6%) and two lethal ventricular arrhythmia in the control group. Thirty-one patients in the NMES group (91%) and 33 patients in the control group (84%) completed the planned sessions during hospitalization. This study fulfilled the preset feasibility criteria. CONCLUSIONS: NMES is feasible in patients with AHF from immediately after admission.
Subject(s)
Electric Stimulation Therapy/methods , Heart Failure/complications , Heart Failure/therapy , Wasting Syndrome/etiology , Acute Disease , Aged , Aged, 80 and over , Atrial Fibrillation/epidemiology , Atrial Fibrillation/physiopathology , Blood Pressure/physiology , Chronic Disease , Dyspnea/complications , Electric Stimulation Therapy/adverse effects , Feasibility Studies , Female , Heart Failure/rehabilitation , Heart Rate/physiology , Hemodynamics/physiology , Hospitalization/statistics & numerical data , Humans , Immobilization/statistics & numerical data , Male , Middle Aged , Muscle, Skeletal/growth & development , Muscle, Skeletal/physiopathology , Tachycardia, Supraventricular/epidemiology , Tachycardia, Supraventricular/physiopathology , Ventricular Flutter/epidemiology , Ventricular Flutter/mortality , Ventricular Flutter/physiopathology , Wasting Syndrome/metabolism , Wasting Syndrome/prevention & control , Wasting Syndrome/rehabilitationABSTRACT
Efforts to reduce the impact of stunting have been largely independent of interventions to reduce the impact of wasting, despite the observation that the conditions can coexist in the same child and increase risk of death. To optimize the management of malnourished children-who can be wasted, stunted, or both-the relationship between stunting and wasting should be elaborated. We aimed to describe the relationship between concurrent weight and height gain during and after rehabilitation from severe wasting. We conducted a secondary analysis of a randomized trial for the outpatient treatment of severe wasting, including 1,542 children who recovered and were followed for 12 weeks. We described the overlap of stunting and severe wasting and the change in stunting over time. We showed the relationship between concurrent weight and height gain using adjusted generalized estimating equations and calculated the mean rate of change in weight-for-height z score (WHZ) and height-for-age z score (HAZ) during and after rehabilitation. At baseline, 79% (n = 1,223/1,542) and 49% (n = 757/1,542) of children were stunted and severely stunted, respectively. Prevalence increased over time among children <24 months. During rehabilitation when weight was not yet fully recovered, we found rapid WHZ gain but limited HAZ gain. Following successful rehabilitation, WHZ gain slowed. The rate of HAZ gain was negative after rehabilitation but increased relative to the period during treatment. The potential relationship between weight and height gain calls for increased coverage of wasting treatment to not only prevent child mortality but also reduce linear growth faltering.
Subject(s)
Body Weight/physiology , Infant Nutrition Disorders , Wasting Syndrome , Body Height/physiology , Female , Growth Disorders/epidemiology , Growth Disorders/rehabilitation , Humans , Infant , Infant Nutrition Disorders/epidemiology , Infant Nutrition Disorders/rehabilitation , Male , Niger/epidemiology , Prospective Studies , Wasting Syndrome/epidemiology , Wasting Syndrome/rehabilitationABSTRACT
INTRODUCTION: In Guillain-Barré syndrome (GBS), patients often develop muscle atrophy from denervation and immobilization. We, therefore, conducted a pilot study of neuromuscular electrical stimulation (NMES) to evaluate feasibility, safety, and effect on muscle wasting in the early phase of GBS. METHODS: Seventeen patients were randomized to receive 20 min of muscle fiber stimulation followed by 40 min of NMES of the right or left quadriceps muscle with the untreated side as control. Cross-sectional area (CSA) of the muscle measured by ultrasound and isometric knee extensor strength were the primary and secondary outcome measures. RESULTS: No treatment related adverse effects were recorded. Change in CSA was -0.25 cm2 (confidence interval [CI], -0.93-0.42) on the stimulated side versus -0.60 cm2 (CI, -1.32-0.11) on the nonstimulated side (P = 0.08). No effect was observed on muscle strength. CONCLUSIONS: NMES seems safe and feasible in the early phase of GBS. Further studies are needed to explore effect on muscle function. Muscle Nerve 59:481-484, 2019.
Subject(s)
Electric Stimulation Therapy/methods , Guillain-Barre Syndrome/rehabilitation , Adult , Aged , Anatomy, Cross-Sectional , Electric Stimulation Therapy/adverse effects , Feasibility Studies , Female , Guillain-Barre Syndrome/diagnostic imaging , Humans , Isometric Contraction , Knee/physiopathology , Male , Middle Aged , Muscle Strength , Muscle, Skeletal/physiopathology , Pilot Projects , Treatment Outcome , Ultrasonography , Wasting Syndrome/diagnostic imaging , Wasting Syndrome/rehabilitation , Young AdultABSTRACT
Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global health burden. A significant proportion of patients experience skeletal muscle wasting and loss of strength as a comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present, the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in development for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in COPD patients.
Subject(s)
Pulmonary Disease, Chronic Obstructive/complications , Wasting Syndrome/drug therapy , Wasting Syndrome/etiology , Anabolic Agents/pharmacology , Anabolic Agents/therapeutic use , Animals , Antioxidants/pharmacology , Antioxidants/therapeutic use , Cytokines/metabolism , Disease Progression , Exercise , Glutathione/biosynthesis , Humans , Inflammation/physiopathology , Inflammation Mediators/metabolism , Muscle, Skeletal/metabolism , Myostatin/antagonists & inhibitors , NADPH Oxidases/antagonists & inhibitors , NF-E2-Related Factor 2/agonists , Oxidative Stress/physiology , Pulmonary Disease, Chronic Obstructive/physiopathology , Pulmonary Disease, Chronic Obstructive/rehabilitation , Quality of Life , Severity of Illness Index , Wasting Syndrome/physiopathology , Wasting Syndrome/rehabilitationABSTRACT
BACKGROUND AND OBJECTIVE: Nutritional depletion in chronic obstructive pulmonary disease (COPD) adversely affects health status and mortality. We aimed to evaluate the effects of nutritional supplementation (NS) with pulmonary rehabilitation (PR) on body composition, mid-thigh cross-sectional area (CSA), dyspnoea, exercise capacity, health-related quality of life, anxiety and depression in advanced COPD patients. METHODS: Forty-six patients were randomized to PR and nutritional support (PRNS), PR or the control group. Dyspnoea was measured with Medical Research Council and BORG scales. Exercise capacity was measured through 6-min walk test and shuttle tests; health-related quality of life was assessed with St. George's Respiratory Questionnaire. Psychological status was measured with Hospital Anxiety and Depression Scale. Body weight and body mass indexes (BMI) were also evaluated. Fat-free mass was measured through bioelectrical impedance analyser. The CSA of quadriceps was calculated in mid-level of the thigh with magnetic resonance imaging. RESULTS: Dyspnoea and total scores of St. George's Respiratory Questionnaire improved in both groups (P < 0.05). Six-minute walk test and incremental shuttle walk test distances in PRNS and PR patients increased significantly as (62.6 ± 42.4 m, 43.3 ± 59.2 m, both P = 0.001; and 63.3 ± 70.1 m and 69.3 ± 69.7 m, both P = 0.001). Although anxiety improved in both groups (P < 0.05), there was no change in depression. Body weight, BMI and fat-free mass index (FFMI) (1.1 ± 0.9 kg, 0.2 ± 1.4 kg/m(2) and 0.6 ± 0.5 kg/m(2), P < 0.05) in PRNS, whereas body weight and FFMI (0.6 ± 0.7 kg, 0.1 ± 0.6 kg/m(2) P < 0.05) increased in PR after the intervention. There was a significant increase in mid-thigh CSA (2.5 ± 4.1 cm(2)) only in PRNS (P = 0.04). CONCLUSION: The combination of NS with PR resulted in improvements particularly in lean body mass and mid-thigh CSA. This study suggests combining NS with PR in reversing weight loss and muscle wasting in COPD.
Subject(s)
Dietary Supplements/statistics & numerical data , Exercise Therapy/methods , Health Status , Nutritional Support/methods , Pulmonary Disease, Chronic Obstructive/rehabilitation , Wasting Syndrome/rehabilitation , Follow-Up Studies , Humans , Prospective Studies , Pulmonary Disease, Chronic Obstructive/complications , Quality of Life , Surveys and Questionnaires , Treatment Outcome , Wasting Syndrome/etiologyABSTRACT
BACKGROUND: Ready-to-use food in the form of biscuits (RUF-Nias biscuit) was locally produced for rehabilitation of moderately and mildly wasted (weight-for-height z-score > or = -3 to < -1.5 SD) children on Nias Island, Indonesia. Daily programs were performed in semiurban settings, and weekly programs took place in rural areas. OBJECTIVE: To analyze the cost of daily and weekly distribution and supervision of RUF-Nias biscuit programs. METHODS: The costs of the daily and weekly programs were derived from the financial report and interviews with program implementers and participating households. Costs were calculated on the basis of total rehabilitation costs per child per day required to achieve a target weight-for-height z-score > or = -1.5 SD in daily and weekly programs. RESULTS: Institutional costs to the implementing organization were similar for both programs (approximately US $4 per child per day). The daily programs resulted in a significantly higher proportion of recovered children (78.6% vs. 65.4%) and higher weight gain (3.7 vs. 2.2 g/kg/day) than the weekly programs. About 6% to 7% of the total cost of the programs was accounted for by locally produced RUF-Nias biscuits. The social cost borne by the community for the weekly programs was about half that for the daily programs. CONCLUSIONS: The daily programs achieved better results for the implementing organization than the weekly programs; however, the weekly programs were preferred by the community because of the lower time constraints and the lower opportunity cost of time. The willingness of community and household members to invest their time in more intensive activities in the daily programs led to better program outcomes.
Subject(s)
Costs and Cost Analysis , Delivery of Health Care/economics , Wasting Syndrome/diet therapy , Child, Preschool , Dietary Supplements , Fast Foods , Female , Humans , Indonesia , Infant , Male , Malnutrition/diet therapy , Rural Population , Time Factors , Urban Population , Wasting Syndrome/rehabilitation , Weight GainABSTRACT
BACKGROUND: Muscle wasting and decreased muscle oxidative capacity commonly occur in patients with chronic obstructive pulmonary disease (COPD). Polyunsaturated fatty acids (PUFA) have been shown to mediate several inflammatory and metabolic pathways which may be involved in the pathogenesis of muscle impairment in COPD. The aim of this study was to investigate the effect of PUFA modulation on systemic inflammation, reversal of muscle wasting, and functional status in COPD. METHODS: Eighty patients with COPD (57 men) with forced expiratory volume in 1 second (FEV1) 37.3 (13.8)% predicted received 9 g PUFA or placebo daily in a double blind randomised fashion during an 8 week rehabilitation programme. Body composition (bioelectrical impedance), functional capacity (lung function, incremental cycle ergometry test, submaximal cycle test, isokinetic quadriceps strength) and inflammatory markers (C-reactive protein (CRP), interleukin (IL)-6 and tumour necrosis factor (TNF)-alpha) were assessed at baseline and after 8 weeks. RESULTS: Both groups had similar increases in weight, fat-free mass (FFM), and muscle strength. The peak load of the incremental exercise test increased more in the PUFA group than in the placebo group (difference in increase 9.7 W (95% CI 2.5 to 17.0), p = 0.009) even after adjustment for FFM. The duration of the constant work rate test also increased more in patients receiving PUFA (difference in increase 4.3 min (95% CI 0.6 to 7.9), p = 0.023). The positive effects of PUFA could not be attributed to a decrease in systemic levels of CRP, IL-6 and TNF-alpha. CONCLUSIONS: This is the first study to show beneficial effects of PUFA on exercise capacity in patients with COPD.